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Economic evaluation and EBM 
Abstract 
In the world of textbook economics, the "sovereign" consumer weighs up the (freely available) evidence 
on the costs, risks, harms and benefits before purchasing health care. The value that consumers then 
attach to the evidence and the expected outcomes is revealed through their purchasing decisions in the 
market. Ultimately, the consumer's decision represents the best or benefit maximising choice given the 
available information. The notion of this evidence-based market is however a long way from the reality of 
health care in Australia. Consumers (that is, patients) generally do not have current best evidence to hand. 
The same could be said of their agent (doctor) prior to worldwide interest in evidence-based medicine 
(especially through the Cochrane Collaboration). If the market is not capable of integrating external 
clinical evidence from systematic research and clinical expertise such that consumers (or their agents for 
that matter) can assess the quality of information easily then a mechanism is needed to perform that 
function. One such mechanism is economic evaluation. This approach describes a set of techniques, 
such as cost-effectiveness analysis and cost-benefit analysis, that require the systematic comparison of 
the costs and benefits of the full range of health care activities. Economic evaluation performs what 
individual consumers would otherwise do in a competitive market; it weighs up the costs and benefits of 
the available choices. That still leaves many questions about whose values count in the aggregation of 
costs and benefits and whether the value of the total is greater than the sum of individual values. 
Nonetheless, if one of the aims of a health care system is to be efficient, then choosing those programs 
that provide the greatest benefits for the resources available will delivery an efficient allocation of health 
care resources. Allocating health care resources is seldom simply a matter of choosing efficient 
programs; the 'fairness' or equity of resource allocation is also a desirable economic goal. The aim of this 
paper is to provide a brief account of what economic evaluation has achieved and could achieve in cancer 
control within an EBM environment. The first part looks at funding lor health services based on evidence 
of economic evaluation. The following section of the paper highlights some innovative research into the 
use of EBM to elicit consumer preferences for colorectal cancer screening. 
Keywords 
ebm, economic, evaluation 
Disciplines 
Education | Social and Behavioral Sciences 
Publication Details 
Salkeld, G. (1999). Economic evaluation and EBM. Cancer Forum, 23 (3), 144-145. 
This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/2635 
陣込
ECONOMIC EVALUATION AND EBM 
G Salkeld 
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Introduction 
In the world 01 textbook economics， the“sovereign" con-
sumer weighs up the (Ireely available) evidence on the costs， 
risks， harms and benelits before purchasing health care. The 
value that consumers Ihen allach 10 Ihe evidence and Ihe 
expecled oulcomes is revealed Ihrough Iheir purchasing de日s-
ions in the market. Ultimately， the consumer's decision repre-
sents Ihe besl or benelil maximising choice given Ihe avai卜
able inlormalion. The nol旧n01 Ihis evidence-based markel is 
however a long way lrom the realily 01 heallh care in Auslralia 
Consumers (Ihal is， palienls) generally do nol have current 
besl evidence to hand. The same could be said 01 Iheir agent 
(doclor) priorto worldwide inleresl in evidence-based medicine 
(especially Ihrough Ihe Cochrane Collaboralion).1f Ihe market 
is nol capable 01 inlegraling exlernal clinical evidence Irom 
syslemalic research and clinical experlise such Ihat con-
sumers (or Iheir agenls lor Ihal matter) can assess the qualily 
01 information easily then a mechanism is needed to perforn川
thallunct旧n.One such mechanism is economic evaluation 
This approach describes a sel 01 techniques， such as cosl-
effecliveness analysis and cosl-benelil analysis， thal require 
the systematic comparison 01 Ihe cosls and benelits 01 Ihe 
ful range 01 health care activities. Economic evaluation 
performs what individual consumers would otherwise do in a 
competilive market; il weighs up the cosls and benelils ollhe 
available choices. That slil leaves many queslions about 
whose values counl in the aggregal旧n01 costs and benefits 
and whelher Ihe value 01 Ihe tolal is grealer than the sum 01 
individual values. Nonelheless， il one 01 the aims 01 a heallh 
care system is 10 be efficienl， Ihen choosing Ihose programs 
thal provide Ihe grealesl benelits lor Ihe resources available 
wil d剖iveryan ellicient al∞ation 01 health care resources 
Allocaling heallh care resources is seldom simply a matter 01 
choosing efficient programs; the 'fairness' or equity of reSQurce 
allocation is aiso a desirable economic goal.1 
The aim 01 Ihi~ paper is 10 provide a briel account 01 whal 
economic evaluation has achieved and could achieve in cancer 
. conlrol wilhin an EBM environment. The lirsl parl looks at 
lunding lor heallh services based on evidence 01 economic 
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innovative research into the use 01 EBM to elicit consumer 
preferences for colorectal cancer screening 
Funding for Success 
If EBM locuses on Ihe use 01“cu打entbest evidence in 
making decisions aboul Ihe ca陪 01individual palienls"2 then 
economic evaluation tends to 10cus on the use 01 current best 
evidence about resource a目∞ationlor groups 01 palienls. Such 
evalualion is relevanl 10 the care 01 individual palienls but that 
is not where il has been mosl successlul. Success has come 
more陪 adilyala systems wide level. For example， in1987， 
Ihe Na古'onalHealth Act， 1953， was amended 10 require Ihe 
Pharma田 ulicalBenelilsAdvisory Committee (PBAC) to 'take 
account 01 compa阻.tiveeffectiveness and cost in recommend田
ing drugs as tharmaceulical benelits.， .'3， Although the 
legislat旧ndid 'nol spec1ly hO"{ Ihis was to be achieved， in
pra，ctfce it hatpenedwilhin an EBMf阻むlework，4，~ Forlhe lirsl 
G.anaefFa(j.J_IT(-¥to[-?~t -No吾Nove而6e-r-f99'9
lime in Ihe world， governmenl lunding lor Ihe reir、bursemenl
01 drugs depended on a syslematic review 01 al relevant 
evidence 01 acceplable scienlilic rigour. The Pharmaceulical 
Evalualion Scheme (PES) is supporled by an inslilutional 
slruclure Ihal critically appraises each cosl-effecliveness 
submission. The effecl 01 Ihis scheme over Ihe lasl six years 
has been to reward drugs Ihal demonstrale clinical superiority 
with a higher price Ihan the compa阻 lordrug. There is a very 
clear incemtive 10r drug companies to pursue research and 
developmenl 01 drugs thal do offer a clinical advanlage over 
currenl Iherapy and Ihen 10 evaluate their cost-effecliveness 
in a s_ystematic and scientifically rigorous manner， 
In Ihe area 01 cancer drugs， the emergence 01 Inlerferon 
(IFN) as an anlicancer agenl p冊 datesIhe PES but the 
polenlial gains 10 be made Irom Ihe proper exploitalion 01 IFN 
are great. Bul so 100 are the∞sts 01 unrestricted and inefficient 
use 01 IFN. The EBM Iramework lor the reimbursemenl 01 
phar仔1aceuticalsallows drugS such as IFN to be subjecled 10 
proper econon川icscrutiny. ~ 
Using Evidence to elicit Consumer Preferences 
for Cancer Screening and CancerTreatment 
In December 1996， The Clinical Oncological Sociely 01 
Australia (COSA) and the Aust悶 lianCancer Nelwork (ACN) 
auspiced a process to develop evidence-based guidelines for 
the prevention， detection and management of colorectal 
can田 r(CRC)J Guidelines are a necessary slep in improving 
medical decis旧nmaking. The qu白 t旧nthen arises， how do 
patients and citizens best use evidence日 basedinformation for 
their own treatment and screening choices? Interest in meas-
uring palient prelerences， palienl parlicipal旧nin screening 
and treatment choices， the use 01 decision aids and communic-
alion 01 inlormation belween doctor and palienl has grown 
wilh Ihe worldwide interest in EBM. In conjunclion刷Ihmy 
colleagues Jeanette Ward， Michael Solomon and Leonie 
Short， I arn conducting a study to elicit consumer preferences 
for colorectal cancer screening. A measurement technique， 
known as discrete choice modelling， isbeing used to provide 
a quantitative estimate of which 1actors of CRC screening and 
its outcomes matter m田 110cilizens and by how muchB.9The 
technique presents an individual with a series 01 pairwise 
choices， each offering different combinalions 01 harms and 
benelils.lO An example 01 a typical scenar旧 ispresented in 
Figure 1. 
Q1.Co叫dyou凶easecompare the two programs and tel me 
whether you would prefer Program A， program B or No Screening? 
Example Scenario Program A Program B No Screening 
Number of bowel cancer 
deaths prevented 3 14 。
Number of unnecessary 
colonoscopies 9日 11，200 。
Notification of a negative 
test result Yes Y包s
ωfease t制ronebox) 
口 口 口
Which would you prefe円 PreferA Prefer B No Screening 
Figure 1 
In Ihis example， the respondenl has been lold Ihat Ihe 
quesl旧nSare based on a CRC screening program where 
10，0唱omen and women aged 50-69 yea陪 havea faecal occult 
blood lesl every second year lor 10 years. In Figure 1， Ihe 
subject is being asked 10 trade-o計anextra 9 bowel cancer 
deaths ave巾 dlor an exlra 10，300 colonoscopies (due 10 a 
lalse positive resull). Prior 10 being offered the choice， su同ects
are given a lay description of what is involved in the screeninQ 
process and in having a ∞lonoscopy. By allering Ihe level 01 
harms and bene1its in subsequent choice questions， a point 
is reached where the respondent is indifferent to a combination 
01 harms and benelils. The process 01 Irading involves 
weighing up Ihe evidence presented in each 01 the scenarios 
The in1ormation contained in each 01 the scenarios is based 
on the mean value and 95% confidence limits for the harms 
and benelits as reported in Ihe Nottingham and Funen Irials 
of biennial CRC screening.1-12 In this way， individuals are 
being asked 10 weigh up Ihe besl available exlernal evidence 
on screening. The next slage 01 Ihe project wil inlroduce cost 
as a choice variabJe in screening 
Conclusion 
The applical旧nof economic evaluation within a clinicalf 
EBM lramework has been' mosl successlul al Ihe syslem wide 
level. It is encouraging to see that the principles of econoniic 
evaluation wil be incorporated into the activities 01 the new 
Medicare Services Advisory Committee. H_owever， the impact 
01 economic evaluation on clinicians making decisions about 
Ihe care 01 individual patienls or on people being ollered 
cancer screening services is less than impressive. New 
approaches such as discrete choice modelling are needed to 
help consumers weigh up the costs， risk， harms and bene1its 
01 screening or treatment options so that the consumer_ can 
make Ihe besl (evidence-based) choice. 
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PSYCHOSOCIAL CARE AND SUPPORT 
FOR CANCER PATIENTS 
P Bulow 
lit1edical Psycho~ogyUnit， University 01 Sydney and 
Department 01 Psychological Medicine， Royal North Shore 
Hospital， Sydney， NSW 
The diagnosis and treatment 01 cancer can present a major 
challenge 10. palients bolh in the shorl and long-Ierm， and 
anxiety and depression are not uncommon-responses. Report-
ed prevalence rales 01 psychological distress in cancer palIents 
r~n~e 1rom. 20~66，% 1， inco~parison to a 5.8% pr剖 alencerate 
01 depression in Ihe general populalion， eslimaled in Ihe US2 
A considerable literalure has developed addressing quesl旧ns
concerning oplimal melhods 10 prevent and ameliorale Ihis 
distress 
Sludies on psychosocial care and supporl lor cancer 
palients have lended 10 locus on either (i) Ihe provision 01 
supporl and counselling or (i) the provision 01 inlormalion 
~nd 1acilitation 01 decision-making3， Psychosocial clinical prac-
tice guidelines encompass川 9bolh Ihese areas have recently 
been developed by Ihe National Breasl Cancer Cenlre， and 
Ihese are currenlly being reviewed under Ihe auspices ollhe 
NHMRC. While locusing on breasl cancer， much 01 Ihe conlent 
01 these guidelines is generalisable to the wider cancer context 
Supporl by bolh the Irealmenl leam and specialisl provid-
ers， such as psychialrists， psychologisls and social workers， 
has been widely studied. There are how a number 01 meta-
analyses 01 randomised conlrolled Irials (RCTs) in this area 
showing Ihat psychological inlervenlions improve 1he well-
bei~!l. .':'1 cancer palienls. For example， ina meta-analysis 01 
45 RCT s with adulls wilh cancer， those receiving psychological 
thera:pies had on average a significant improvement 01 12% 
in emotional adjustment. 10% in social functioning， 15% in 
treatment-and disease-related symptoms and 14% in overall 
improvement in Iheir qualily 01 lile， compared 10 those nol 
receiving psychological therapy4 
Greater effects have been observed when therapies were 
provided over longer periods， and conducled by more highly 
Irained Iherapisls， such as a specially Irained counsellor， 
nurse， psychologist orsocial worke，s. However， lew differences 
have been observed between dillerenl Iyp田 01Iherapy (such 
as cognitive-behavioural Iherapy， lamily and/or couple Iherapy， 
or psycho-educalional therapy) or lormats 01 therapy (su凶
as group or individual sessions)， suggesting Ihal leatures 
common 10 al psychosocial Iherapies， such as empalh民listen-
in9， affirmation and reassurance， have the greatest impact 
More controversiall弘somenaturalistic， prospective sludies 
ha~e de~onst_rat~d an as~ociation between patient coping 
slyle and lenglh 01 survivat6， and a small number 01 randomis~ 
ed controlled Irials have produced a higher level 01 evidence 
for an associat旧nbetween psychosocial lactors and oulcome 
Speigel' reported Ihal women wilh melaslatic breast cancer 
旧 ndomised10 a psychosocial inlervenlion group sur叫vedlor 
Iwice as long as those receiving slandard Ireatment， while 
Fawzy el al8 reported signilicanl changes in immunological 
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